Skip to main content Skip to search Skip to main navigation

UN: Cannabis removed from Schedule IV of most dangerous drugs

As announced by the UN Commission on 2 December 2020, cannabis was removed from Schedule IV of the 1961 Single Convention on Narcotic Drugs following WHO's recommendation.

The 53 members of the Commission on Narcotic Drugs (CND), the UN's central body for drug policy decisions, voted conceivably close with 27 in favor, 25 against and one abstention. Cannabis was placed in Schedule IV for 59 years, along with heroin and carfentanil. Schedule IV substances are considered "particularly harmful and of extremely limited medical or therapeutic value". Now cannabis has been moved to Schedule I, where methadone and cocaine are listed, as well. However, its use for non-medical and non-scientific purposes is still illegal.  

Background  

The WHO had already submitted six recommendations on cannabis and related substances in January 2019. However, many countries asked for more time to deal with the matter.   

Current status  

Currently, more than 50 countries have adopted programs on medical cannabis. Canada, Uruguay and 15 US states have legalized its recreational use. In Mexico and Luxembourg this is already discussed. 


Source:

UN: UN commission reclassifies cannabis, yet still considered harmful 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA: Revision of Annex 6 - Manufacture of Medicinal Gases

EMA and PIC/S have published a concept paper announcing a targeted revision of Annex 6 Manufacture of Medicinal Gases of the EU GMP Guide. The last update dates from 2010. The revision aims to reflect current manufacturing practice, technological progress and lessons learned from the COVID-19 pandemic.

Read more
EMA: Concept Paper on the Revision of Annex 15

EMA: Concept Paper on the Revision of Annex 15

EMA and PIC/S have published a concept paper outlining a targeted revision of Annex 15 (Qualification and Validation).

Read more
What do Typical Manufacturing Processes for Sterile Products look like?

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:
Read more
Human Resource Management as a Key to Success

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

Read more
EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

Read more
EMA: Discussions on the Revised ERA Guideline

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.
Read more
Previous
Next